119 related articles for article (PubMed ID: 33999509)
21. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
23. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
24. Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.
Nair S; Zlotnick A
J Virol; 2018 May; 92(10):. PubMed ID: 29491156
[TBL] [Abstract][Full Text] [Related]
25. Apobec3G-Based Strategies to Defeat HIV Infection.
Ran X; Ao Z; Yao X
Curr HIV Res; 2016; 14(3):217-24. PubMed ID: 26957196
[TBL] [Abstract][Full Text] [Related]
26. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
[TBL] [Abstract][Full Text] [Related]
27. USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV-1 replication.
Pan T; Song Z; Wu L; Liu G; Ma X; Peng Z; Zhou M; Liang L; Liu B; Liu J; Zhang J; Zhang X; Huang R; Zhao J; Li Y; Ling X; Luo Y; Tang X; Cai W; Deng K; Li L; Zhang H
Elife; 2019 Aug; 8():. PubMed ID: 31397674
[TBL] [Abstract][Full Text] [Related]
28. B-cell agonists up-regulate AID and APOBEC3G deaminases, which induce IgA and IgG class antibodies and anti-viral function.
Seidl T; Whittall T; Babaahmady K; Lehner T
Immunology; 2012 Mar; 135(3):207-15. PubMed ID: 22044427
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells.
Pido-Lopez J; Whittall T; Wang Y; Bergmeier LA; Babaahmady K; Singh M; Lehner T
J Immunol; 2007 Feb; 178(3):1671-9. PubMed ID: 17237417
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Antiviral Innate Immunity Through APOBEC Ribonucleoprotein Complexes.
Salter JD; Polevoda B; Bennett RP; Smith HC
Subcell Biochem; 2019; 93():193-219. PubMed ID: 31939152
[TBL] [Abstract][Full Text] [Related]
31. The Enzymatic Activity of APOBE3G Multimers.
Pan Y; Zagorski K; Shlyakhtenko LS; Lyubchenko YL
Sci Rep; 2018 Dec; 8(1):17953. PubMed ID: 30560880
[TBL] [Abstract][Full Text] [Related]
32. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
33. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
34. Structural Investigations on the Interactions between Cytidine Deaminase Human APOBEC3G and DNA.
Yan X; Lan W; Wang C; Cao C
Chem Asian J; 2019 Jul; 14(13):2235-2241. PubMed ID: 31116511
[TBL] [Abstract][Full Text] [Related]
35. Zinc-mediated binding of a low-molecular-weight stabilizer of the host anti-viral factor apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G.
Radwan MO; Sonoda S; Ejima T; Tanaka A; Koga R; Okamoto Y; Fujita M; Otsuka M
Bioorg Med Chem; 2016 Sep; 24(18):4398-4405. PubMed ID: 27475536
[TBL] [Abstract][Full Text] [Related]
36. Differential Contributions of Ubiquitin-Modified APOBEC3G Lysine Residues to HIV-1 Vif-Induced Degradation.
Turner T; Shao Q; Wang W; Wang Y; Wang C; Kinlock B; Liu B
J Mol Biol; 2016 Aug; 428(17):3529-39. PubMed ID: 27297094
[TBL] [Abstract][Full Text] [Related]
37. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
Bouzidi MS; Caval V; Suspène R; Hallez C; Pineau P; Wain-Hobson S; Vartanian JP
J Mol Biol; 2016 Aug; 428(17):3514-28. PubMed ID: 27289067
[TBL] [Abstract][Full Text] [Related]
39. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.
Grant M; Larijani M
AIDS Res Ther; 2017 Sep; 14(1):44. PubMed ID: 28893290
[TBL] [Abstract][Full Text] [Related]
40. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
